Erratum to: Calcium/Calmodulin-Dependent Protein Kinase II and Eukaryotic Elongation Factor 2 Kinase Pathways Mediate the Antidepressant Action of Ketamine.

Biol Psychiatry July 14, 2026 correction DOI: 10.1016/j.biopsych.2026.06.020 (opens in new tab)

Study at a glance

AI-extracted from the abstract

Topics	Esketamine Ketamine

Abstract

Erratum to: Calcium/Calmodulin-Dependent Protein Kinase II and Eukaryotic Elongation Factor 2 Kinase Pathways Mediate the Antidepressant Action of Ketamine.

Erratum to "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study" [European Neuropsychopharmacology 107 (2026) 112801]. Eur Neuropsychopharmacol August 27, 2026
Correction. Ketamine vs Electroconvulsive Therapy in the Management of Treatment-Resistant Depression: Do We Need More Data? The Journal of Clinical Psychiatry February 11, 2025
Corrigendum to "Intranasal esketamine in treatment-resistant depression: long-term dosing patterns and clinical outcomes in a 5-year observational study". Ther Adv Psychopharmacol May 19, 2026
Corrigendum: A cohort-based case report: The impact of ketamine-assisted therapy embedded in a community of practice framework for healthcare providers with PTSD and depression. Frontiers in Psychiatry 2022
Extending ketamine's antidepressant effects. Science (New York, N.Y.) May 8, 2025 9 citations

Study at a glance

Abstract

Related reading